ArticleBritish journal of haematology2022

Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.

John N Allan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.